Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Several biosimilar agents to infliximab and adalimumab are currently FDA-approved, with many more currently in development. Initial clinical trials for approval have been conducted in one of the original indications for each originator biologic. There are growing data demonstrating similar clinical efficacy, immunogenicity, and safety of each of the approved infliximab and adalimumab biosimilars, both through indication extrapolation from other diseases such as rheumatoid arthritis and ankylosing spondylitis, as well observational data in patients with inflammatory bowel disease. Further research is ongoing regarding the efficacy and safety of substitution and interchangeability of biosimilars, as well as therapeutic drug monitoring for biosimilar agents. Research to date supports the utilization of reference biologics and biosimilars for new initiators, while additional data are being accrued regarding the interchangeability between these agents.
|
Authors | Frank I Scott, Gary R Lichtenstein |
Journal | Current treatment options in gastroenterology
(Curr Treat Options Gastroenterol)
Vol. 16
Issue 1
Pg. 147-164
(Mar 2018)
ISSN: 1092-8472 [Print] United States |
PMID | 29492747
(Publication Type: Journal Article, Review)
|